A double-blind, 4-period crossover, abuse liability study assessing clinical abuse of Opana extended release and oxymorphone HCl powder in healthy non-dependent opioid users.

Trial Profile

A double-blind, 4-period crossover, abuse liability study assessing clinical abuse of Opana extended release and oxymorphone HCl powder in healthy non-dependent opioid users.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Oxymorphone (Primary) ; Oxymorphone (Primary)
  • Indications Pain
  • Focus Pharmacodynamics
  • Most Recent Events

    • 09 Jun 2016 New trial record
    • 14 May 2016 Primary endpoint has bee met (Median difference for Emax) as per an abstract presented at the 35th Annual Scientific Meeting of the American Pain Society
    • 14 May 2016 Results presented at the 35th Annual Scientific Meeting of the American Pain Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top